Mindaugas Galvosas, MD
@mgalvosas.bsky.social did:plc:obfvh5sbhlapv2nooimkthu3
Neuroscience Digital Biomarkers @ indivi.io | prev. cough as a digital biomarker @ hyfe.com; founder of wandering prevention tech for dementia | interested in Digital Health | my opinions
No Bluesky desde
- Seguidores
- 4.072
- Seguindo
- 2.253
- Posts
- 991
- Dias nos rankings
- 0
Resumo
Mindaugas Galvosas, MD (@mgalvosas.bsky.social) é um usuário do Bluesky desde 7 fevereiro 2024. Tem 4.072 seguidores, segue 2.253 contas e publicou 991 posts.
Aparições nos rankings
Os melhores dias em que posts desta conta entraram na lista diária do Debya.
Esta conta ainda não apareceu em um ranking diário.
Posts curtidos recentemente
Curtidas públicas da rede Bluesky.
Giving up on deep space tonight with such a bright, but beautiful moon! #astrophotography
Ver postIf you haven’t read it yet👇 Sample Size and Power Calculations Based on Endpoint Responsiveness: Applications to Trials of Disease-Modifying Therapies in Parkinson’s Disease www.medrxiv.org/content/10.6...
Ver postIt was a really successful International Parkinson and Movement Disorder Society congress in Seoul this year for Indivi #MDSCongress #MDS2026
Ver postDo all DM1 therapies need to be oligonucleotides? What about: -> small molecules? -> engineered RNA-binding proteins? -> gene and repeat targeting? -> drug repurposing? Future DM1 therapies discussed at #WMS2026 will extend beyond oligonucleotides alone
Ver postIn his #WMS2026 talk "Advances in Translational Therapeutics for DM1," Prof. Masayuki Nakamori (Yamaguchi University) highlighted how quickly the DM1 pipeline has matured, and also what remains to be solved: the endpoint
Ver post
Contas que bloqueia
No Bluesky, bloqueios são registros públicos.
